trans-2-Aethyl-cyclohexylamin | 1104944-61-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: trans-2-Aethyl-cyclohexylamin
• 英文别名: (1S,2S)-2-ethylcyclohexan-1-amine
• CAS: 1104944-61-7
• 化学式: C₈H₁₇N
• 分子量: 127.23
• InChiKey: QOPVVDFTPKWSFL-YUMQZZPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  trans-2-Aethyl-cyclohexylamin 、 2-氯-6-甲基-5-硝基-4(1h)-嘧啶酮 以 氯仿 为溶剂， 生成
  参考文献：
  名称：

  SAR studies on a novel series of human cytomegalovirus primase inhibitors

  摘要：

  A novel series of imidazolylpyrimidines were found to possess inhibitory activity against the human CMV UL70 primase. Extensive SAR studies on an HTS lead led to potent, orally bioavailable compounds with anti-CMV IC50 values of 150 nM in both viral yield and viral DNA replication assays and with a much reduced cytotoxicity compared to marketed treatments ganciclovir and cidofovir. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.01.109

文献信息

• [EN] ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS<br/>[FR] TRANSAMINATION ENZYMATIQUE D'ANALOGUES DE CYCLOPAMINE
  申请人：INFINITY PHARMACEUTICALS INC

  公开号：WO2011017551A1

  公开（公告）日：2011-02-10

  Provided are processes for the synthesis of amino analogues from ketone starting materials

  提供从酮起始材料合成氨基类似物的过程。
• SUBSTITUTED DIAMINOCARBOXAMIDE AND DIAMINOCARBONITRILE PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH
  申请人：Bennett Brydon L.

  公开号：US20130029987A1

  公开（公告）日：2013-01-31

  Provided herein are Diaminopyrimidine Compounds having the following structures: wherein R 1 , R 2 , R 3 , and R 4 are as defined herein, compositions comprising an effective amount of a Diaminopyrimidine Compound, and methods for treating or preventing liver fibrotic disorders or a condition treatable or preventable by inhibition of a JNK pathway.

  本文提供以下结构的二氨基嘧啶化合物：其中R1、R2、R3和R4的定义如下，在有效量的二氨基嘧啶化合物组成物中，以及用于治疗或预防肝纤维化疾病或可通过抑制JNK途径治疗或预防的疾病的方法。
• ARYL METHYL BENZOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150031713A1

  公开（公告）日：2015-01-29

  The present invention is directed to benzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的苯并喹唑啉酮化合物，其为M1受体正向变构调节剂，并且在治疗M1受体参与的疾病，例如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍方面具有用途。该发明还涉及包含该化合物的制药组合物，以及使用该化合物和组合物治疗由M1受体介导的疾病方面的用途。
• LIGAND COMPOUND, CATALYST SYSTEM FOR OLEFIN OLIGOMERIZATION, AND OLEFIN OLIGOMERIZATION METHOD USING SAME
  申请人：LG Chem, Ltd.

  公开号：EP3214087A1

  公开（公告）日：2017-09-06

  The present invention relates to a ligand compound, a catalyst system for olefin oligomerization, and a method for oligomerizing olefins using the same. The ligand compound according to the present invention has a structure in which a substituent is substituted in the trans form, and thereby when used for olefin oligomerization, the activity of the catalyst used and the selectivity of 1-hexene and 1-octene can be increased.

  本发明涉及一种配体化合物、一种用于烯烃低聚的催化剂体系，以及一种用其低聚烯烃的方法。根据本发明的配体化合物具有以反式形式取代一个取代基的结构，因此当用于烯烃低聚时，所用催化剂的活性和 1-己烯和 1-辛烯的选择性可以提高。
• ENZYMATIC TRANSAMINATION OF CYCLOPAMINE ANALOGS
  申请人：Infinity Pharmaceuticals, Inc.

  公开号：EP2462115A1

  公开（公告）日：2012-06-13